ALLO
Price
$1.42
Change
+$0.13 (+10.08%)
Updated
Jun 6 closing price
Capitalization
282.16M
60 days until earnings call
NTLA
Price
$8.09
Change
+$0.51 (+6.73%)
Updated
Jun 6 closing price
Capitalization
837.99M
54 days until earnings call
Interact to see
Advertisement

ALLO vs NTLA

Header iconALLO vs NTLA Comparison
Open Charts ALLO vs NTLABanner chart's image
Allogene Therapeutics
Price$1.42
Change+$0.13 (+10.08%)
Volume$3.48M
Capitalization282.16M
Intellia Therapeutics
Price$8.09
Change+$0.51 (+6.73%)
Volume$7.21M
Capitalization837.99M
ALLO vs NTLA Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. NTLA commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a StrongBuy and NTLA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ALLO: $1.42 vs. NTLA: $8.09)
Brand notoriety: ALLO and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 105% vs. NTLA: 166%
Market capitalization -- ALLO: $282.16M vs. NTLA: $837.99M
ALLO [@Biotechnology] is valued at $282.16M. NTLA’s [@Biotechnology] market capitalization is $837.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 3 bearish.
  • NTLA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а +21.37% price change this week, while NTLA (@Biotechnology) price change was +17.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

ALLO is expected to report earnings on Aug 06, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($838M) has a higher market cap than ALLO($282M). NTLA YTD gains are higher at: -30.617 vs. ALLO (-33.333). ALLO has higher annual earnings (EBITDA): -243.33M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. ALLO (292M). ALLO has less debt than NTLA: ALLO (90.8M) vs NTLA (119M). NTLA has higher revenues than ALLO: NTLA (45.6M) vs ALLO (22K).
ALLONTLAALLO / NTLA
Capitalization282M838M34%
EBITDA-243.33M-530.8M46%
Gain YTD-33.333-30.617109%
P/E RatioN/AN/A-
Revenue22K45.6M0%
Total Cash292M504M58%
Total Debt90.8M119M76%
FUNDAMENTALS RATINGS
ALLO vs NTLA: Fundamental Ratings
ALLO
NTLA
OUTLOOK RATING
1..100
44
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9492
PRICE GROWTH RATING
1..100
6565
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (24) in the Biotechnology industry is significantly better than the same rating for ALLO (97). This means that NTLA’s stock grew significantly faster than ALLO’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that NTLA’s stock grew similarly to ALLO’s over the last 12 months.

NTLA's SMR Rating (92) in the Biotechnology industry is in the same range as ALLO (94). This means that NTLA’s stock grew similarly to ALLO’s over the last 12 months.

NTLA's Price Growth Rating (65) in the Biotechnology industry is in the same range as ALLO (65). This means that NTLA’s stock grew similarly to ALLO’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that NTLA’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLONTLA
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 17 days ago
89%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMIMX36.76N/A
N/A
FMI Common Stock Investor
IPMSX18.73N/A
N/A
Voya Index Plus MidCap Port S
SGPIX104.79N/A
N/A
ProFunds Small Cap Growth Inv
SSDAX30.69N/A
N/A
DWS Small Cap Growth A
LSITX76.70N/A
N/A
ClearBridge Large Cap Growth IS

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+6.73%
VCYT - NTLA
69%
Closely correlated
+1.78%
CRSP - NTLA
66%
Loosely correlated
+8.53%
BEAM - NTLA
65%
Loosely correlated
+9.26%
RXRX - NTLA
57%
Loosely correlated
+20.13%
ABCL - NTLA
55%
Loosely correlated
+2.95%
More